(NSABP B-64) EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

Objective

Clinical Trial Details

Principal Investigator(s)

Jason Jones, MD

Clinical Trial Categories

• Cancer
• Breast Cancer

Contact

Precision Research Coordinators at 605-322-3228
or precisionresearch@avera.org